|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Indiana University School of Medicine |
|---|---|
| Information provided by: | Indiana University |
| ClinicalTrials.gov Identifier: | NCT00569842 |
Purpose
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
| Condition |
|---|
|
Leukemia Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Hodgkin's Disease Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Disorders Aplastic Anemia Chronic Myelogenous Leukemia |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Investigation of the Cylex® ImmuKnow® Assay |
None to be retained.
| Estimated Enrollment: | 30 |
| Study Start Date: | November 2007 |
| Estimated Study Completion Date: | November 2010 |
| Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| observational |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
Inclusion Criteria:
Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
Contacts and Locations| Contact: Lisa Wood, RN | 317-274-1781 | llwood@iupui.edu |
| Contact: Sherif Farag, MD, PhD | 317-274-0843 | ssfarag@iupui.edu |
| United States, Indiana | |
| Indiana Universtiy Simon Cancer Center | Recruiting |
| Indianapolis, Indiana, United States, 46202 | |
| Principal Investigator: | Sherif Farag, MD, PhD | Indiana University Simon Cancer Center |
More Information
| Responsible Party: | Indiana University Cancer Center ( Sherif Farag, MD, PhD/ Principal Investigator ) |
| Study ID Numbers: | 0710-11/ IUCRO-0207 |
| Study First Received: | December 5, 2007 |
| Last Updated: | January 6, 2009 |
| ClinicalTrials.gov Identifier: | NCT00569842 |
| Health Authority: | United States: Institutional Review Board |
|
Leukemia, Lymphoid Hodgkin's disease Chronic myelogenous leukemia Precancerous Conditions Blood Protein Disorders Hodgkin lymphoma, adult Lymphoma, small cleaved-cell, diffuse Paraproteinemias Hemostatic Disorders Leukemia Preleukemia Hemorrhagic Disorders Multiple myeloma Leukemia, Lymphocytic, Chronic, B-Cell Anemia, Aplastic |
Hodgkin Disease Lymphoma Chronic lymphocytic leukemia Myelodysplastic syndromes Immunoproliferative Disorders Hematologic Diseases Leukemia, B-cell, chronic Blood Coagulation Disorders Myelodysplasia Myelodysplastic Syndromes Myeloproliferative Disorders Anemia Vascular Diseases Leukemia, Myeloid Multiple Myeloma |
|
Neoplasms Pathologic Processes Disease Neoplasms by Histologic Type |
Immune System Diseases Syndrome Cardiovascular Diseases |
